Bank of New York Mellon Corp Trims Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Bank of New York Mellon Corp lessened its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 3.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,977 shares of the company’s stock after selling 5,597 shares during the period. Bank of New York Mellon Corp’s holdings in GoodRx were worth $1,302,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GDRX. Rubric Capital Management LP bought a new stake in shares of GoodRx during the 4th quarter worth approximately $39,348,000. Rip Road Capital Partners LP lifted its position in shares of GoodRx by 25.8% during the fourth quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock worth $11,814,000 after purchasing an additional 361,294 shares during the last quarter. Picton Mahoney Asset Management purchased a new stake in shares of GoodRx during the first quarter valued at $3,467,000. GSA Capital Partners LLP purchased a new stake in shares of GoodRx during the first quarter valued at $1,638,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of GoodRx by 61.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock worth $1,289,000 after purchasing an additional 68,835 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a document filed with the SEC, which is available through this link. 4.17% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on GDRX shares. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. Morgan Stanley boosted their price target on shares of GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. Citigroup lowered their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, UBS Group cut their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.36.

GoodRx Stock Down 3.7 %

Shares of GDRX stock opened at $7.08 on Friday. The stock’s fifty day moving average price is $8.00 and its 200 day moving average price is $7.60. GoodRx Holdings, Inc. has a 1-year low of $4.14 and a 1-year high of $9.26. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -708.00, a price-to-earnings-growth ratio of 3.55 and a beta of 1.38. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ratio of 7.32.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $200.60 million for the quarter, compared to analysts’ expectations of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. GoodRx’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.02 EPS. On average, research analysts expect that GoodRx Holdings, Inc. will post 0.15 earnings per share for the current fiscal year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.